All Articles

With capital ratios that dwarf its peers, Charles Schwab's latest Fed stress test results signal more than just compliance—they reveal a strategic bulwark.

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

Investors eye Alpine Income Property Trust's upcoming Q2 results to gauge the resilience of its unique net-lease and commercial loan strategy amid high inflation.

Alaska Communications appoints Courtland Madock, a veteran of Brightspeed and WOW!, as CEO. We explore her track record and what it means for the state's vital digital future.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

BNED is back in the black, cutting debt and rewarding investors. We analyze the digital strategy behind the turnaround and what it means for the future.

As FormFactor joins the Russell 1000, we decode the 'Russell Effect' and the growth signals that propelled this key semiconductor supplier to new heights.

A $1.4M project aims to revolutionize food production by turning grape skins into gold using AI, but can it truly fix a broken link in our food chain?

As the consumer goods giant prepares its Q2 report, investors will scrutinize if its high-growth brand acquisitions can offset inflation and tariff pressures.

NAVER's venture arm invests in SAZO, a startup whose AI agents automate the messy world of cross-border commerce, from customs to payments.

Friedman Industries just announced its 218th straight quarterly dividend, a rare feat. But what does this signal of reliability mean amid industry shifts and questions about its cash flow?

In a bold strategic shift, Identiv sells its core IoT business to Trackonomy, transforming into a SaaS firm powered by a major stake in the AI leader.

After a Q1 revenue miss, all eyes are on ICF's upcoming Q2 results. Can its booming commercial energy sector offset federal headwinds and validate its ambitious 2026 guidance?

A class-action lawsuit claims First Solar misled investors about its ability to handle U.S. tariffs, leading to stock drops and analyst downgrades.

A new ARPA-H grant aims to replace 50-year-old tech with a rapid blood test for fetal hypoxia, a move that could slash C-sections and save lives.

Work World appoints a new CFO to steer its PE-backed expansion. We dive into the strategy of acquisitions, tech upgrades, and market consolidation.

A new ranking from CNBC spotlights a major industry shift. It’s no longer just about assets; it’s about integrated, tech-enabled fiduciary care.

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

OpenVC's new Unicorn Fund isn't just another fund; it's a systematic attempt to map and monetize the private market frontier where real value now grows.